Literature DB >> 28971872

Kinetics of Sulbactam Hydrolysis by β-Lactamases, and Kinetics of β-Lactamase Inhibition by Sulbactam.

Adam B Shapiro1.   

Abstract

Sulbactam is one of four β-lactamase inhibitors in current clinical use to counteract drug resistance caused by degradation of β-lactam antibiotics by these bacterial enzymes. As a β-lactam itself, sulbactam is susceptible to degradation by β-lactamases. I investigated the Michaelis-Menten kinetics of sulbactam hydrolysis by 14 β-lactamases, representing clinically widespread groups within all four Ambler classes, i.e., CTX-M-15, KPC-2, SHV-5, and TEM-1 for class A; IMP-1, NDM-1, and VIM-1 for class B; Acinetobacter baumannii ADC-7, Pseudomonas aeruginosa AmpC, and Enterobacter cloacae P99 for class C; and OXA-10, OXA-23, OXA-24, and OXA-48 for class D. All of the β-lactamases were able to hydrolyze sulbactam, although they varied widely in their kinetic constants for the reaction, even within each class. I also investigated the inactivation kinetics of the inhibition of these enzymes by sulbactam. The class A β-lactamases varied widely in their susceptibility to inhibition, the class C and D enzymes were very weakly inhibited, and the class B enzymes were essentially or completely unaffected. In addition, we measured the sulbactam turnover number, the sulbactam/enzyme molar ratio required for complete inhibition of each enzyme. Class C enzymes had the lowest turnover numbers, class A enzymes varied widely, and class D enzymes had very high turnover numbers. These results are valuable for understanding which β-lactamases ought to be well inhibited by sulbactam. Moreover, since sulbactam has intrinsic antibacterial activity against Acinetobacter species pathogens, these results contribute to understanding β-lactamase-mediated sulbactam resistance in Acinetobacter, especially due to the action of the widespread class D enzymes.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  kinetics; sulbactam; turnover number; β-lactamase

Mesh:

Substances:

Year:  2017        PMID: 28971872      PMCID: PMC5700308          DOI: 10.1128/AAC.01612-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  41 in total

1.  Kinetics study of KPC-3, a plasmid-encoded class A carbapenem-hydrolyzing beta-lactamase.

Authors:  Jimena Alba; Yoshikazu Ishii; Kenneth Thomson; Ellen Smith Moland; Keizo Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

2.  Interaction between class B beta-lactamases and suicide substrates of active-site serine beta-lactamases.

Authors:  C Prosperi-Meys; G Llabres; D de Seny; R P Soto; M H Valladares; N Laraki; J M Frere; M Galleni
Journal:  FEBS Lett       Date:  1999-01-25       Impact factor: 4.124

3.  A kinetic study of NMC-A beta-lactamase, an Ambler class A carbapenemase also hydrolyzing cephamycins.

Authors:  S Mariotte-Boyer; M H Nicolas-Chanoine; R Labia
Journal:  FEMS Microbiol Lett       Date:  1996-09-15       Impact factor: 2.742

4.  Antimicrobial activity of tigecycline and cefoperazone/sulbactam tested against 18,386 Gram-negative organisms from Europe and the Asia-Pacific region (2013-2014).

Authors:  M A Pfaller; R K Flamm; L R Duncan; R E Mendes; R N Jones; H S Sader
Journal:  Diagn Microbiol Infect Dis       Date:  2017-03-06       Impact factor: 2.803

Review 5.  β-Lactams and β-Lactamase Inhibitors: An Overview.

Authors:  Karen Bush; Patricia A Bradford
Journal:  Cold Spring Harb Perspect Med       Date:  2016-08-01       Impact factor: 6.915

6.  Kinetic Study of Laboratory Mutants of NDM-1 Metallo-β-Lactamase and the Importance of an Isoleucine at Position 35.

Authors:  Francesca Marcoccia; Carlo Bottoni; Alessia Sabatini; Martina Colapietro; Paola Sandra Mercuri; Moreno Galleni; Frédéric Kerff; André Matagne; Giuseppe Celenza; Gianfranco Amicosante; Mariagrazia Perilli
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

7.  Cefoxitin, N-formimidoyl thienamycin, clavulanic acid, and penicillanic acid sulfone as suicide inhibitors for different types of beta-lactamases produced by gram-negative bacteria.

Authors:  T Sawai; K Tsukamoto
Journal:  J Antibiot (Tokyo)       Date:  1982-11       Impact factor: 2.649

8.  Site-directed mutagenesis at the active site of Escherichia coli TEM-1 beta-lactamase. Suicide inhibitor-resistant mutants reveal the role of arginine 244 and methionine 69 in catalysis.

Authors:  M Delaire; R Labia; J P Samama; J M Masson
Journal:  J Biol Chem       Date:  1992-10-15       Impact factor: 5.157

9.  Penicillanic acid sulfone: an unexpected isotope effect in the interaction of 6 alpha- and 6 beta-monodeuterio and of 6,6-dideuterio derivatives with RTEM beta-lactamase from Escherichia coli.

Authors:  D G Brenner; J R Knowles
Journal:  Biochemistry       Date:  1981-06-23       Impact factor: 3.162

10.  Biochemical characterization of CTX-M-15 from Enterobacter cloacae and designing a novel non-β-lactam-β-lactamase inhibitor.

Authors:  Mohammad Faheem; Md Tabish Rehman; Mohd Danishuddin; Asad U Khan
Journal:  PLoS One       Date:  2013-02-21       Impact factor: 3.240

View more
  13 in total

1.  Molecular Epidemiology of Emerging blaOXA-23-Like- and blaOXA-24-Like-Carrying Acinetobacter baumannii in Taiwan.

Authors:  Shu-Chen Kuo; Wei-Cheng Huang; Tzu-Wen Huang; Hui-Ying Wang; Jui-Fen Lai; Te-Li Chen; Tsai-Ling Lauderdale
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

2.  1H, 13C, and 15N backbone resonance assignments for KPC-2, a class A serine-β-lactamase.

Authors:  Jamie VanPelt; Ben A Shurina; Theresa A Ramelot; Robert A Bonomo; Richard C Page
Journal:  Biomol NMR Assign       Date:  2018-12-14       Impact factor: 0.746

3.  Unorthodox Parenteral β-Lactam and β-Lactamase Inhibitor Combinations: Flouting Antimicrobial Stewardship and Compromising Patient Care.

Authors:  Snehal Palwe; Balaji Veeraraghavan; Hariharan Periasamy; Kshama Khobragade; Arun S Kharat
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

Review 4.  Multidrug Resistant Acinetobacter baumannii: Resistance by Any Other Name Would Still be Hard to Treat.

Authors:  David A Butler; Mark Biagi; Xing Tan; Samah Qasmieh; Zackery P Bulman; Eric Wenzler
Journal:  Curr Infect Dis Rep       Date:  2019-11-16       Impact factor: 3.725

5.  Evolutionary Trajectories toward High-Level β-Lactam/β-Lactamase Inhibitor Resistance in the Presence of Multiple β-Lactamases.

Authors:  Fredrika Rajer; Lisa Allander; Philip A Karlsson; Linus Sandegren
Journal:  Antimicrob Agents Chemother       Date:  2022-06-02       Impact factor: 5.938

Review 6.  Treatment of Infections by OXA-48-Producing Enterobacteriaceae.

Authors:  Adam Stewart; Patrick Harris; Andrew Henderson; David Paterson
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191

Review 7.  Interplay between β-lactamases and new β-lactamase inhibitors.

Authors:  Karen Bush; Patricia A Bradford
Journal:  Nat Rev Microbiol       Date:  2019-05       Impact factor: 60.633

8.  Targeting Multidrug-Resistant Acinetobacter spp.: Sulbactam and the Diazabicyclooctenone β-Lactamase Inhibitor ETX2514 as a Novel Therapeutic Agent.

Authors:  Melissa D Barnes; Vijay Kumar; Christopher R Bethel; Samir H Moussa; John O'Donnell; Joseph D Rutter; Caryn E Good; Kristine M Hujer; Andrea M Hujer; Steve H Marshall; Barry N Kreiswirth; Sandra S Richter; Philip N Rather; Michael R Jacobs; Krisztina M Papp-Wallace; Focco van den Akker; Robert A Bonomo
Journal:  mBio       Date:  2019-03-12       Impact factor: 7.867

9.  Interactions of the Diazabicyclooctane Serine β-Lactamase Inhibitor ETX1317 with Target Enzymes.

Authors:  Adam B Shapiro; Ning Gao
Journal:  ACS Infect Dis       Date:  2020-12-10       Impact factor: 5.084

Review 10.  Durlobactam, a New Diazabicyclooctane β-Lactamase Inhibitor for the Treatment of Acinetobacter Infections in Combination With Sulbactam.

Authors:  Adam B Shapiro; Samir H Moussa; Sarah M McLeod; Thomas Durand-Réville; Alita A Miller
Journal:  Front Microbiol       Date:  2021-07-19       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.